Background Major depressive disorder
(MDD) has been linked to episodic memory
deficits that may be improved after pharmacological treatment, but it is unclear whether there is a class of antidepressants
that is more effective than others to ameliorate these deficits in MDD. In addition, the possible effects of clinical and sociodemographic variables on the improvement of MDD memory
deficits after pharmacological treatment are currently unknown. Our aims are to study the possible neuropsychological effects of second-generation antidepressant classes on the episodic memory
of MDD patients and to study the potential effects of clinical and demographic variables as moderators of the effects of antidepressants
on the memory
of depressed patients through a meta-analysis
Nine articles were included in our study. A structural equation model meta-analysis
Our results suggest that selective serotonin reuptake inhibitors and serotonine-noradrenaline reuptake inhibitors would bring about a substantial improvement in the memory
of depressed patients, whereas other antidepressant classes would cause rather modest effects. Our results also suggest that clinical and demographic variables play a very important role as mediators of memory
improvement after MDD treatment. Thus, a relatively low level of symptom severity, a high degree of clinical improvement, a younger age, and more years of education were positively related to memory
improvement after MDD treatment.
Although antidepressant class is an important variable linked to memory
improvement in MDD, overall, the degree of memory
amelioration in depression is very closely related to clinical and demographic variables of patients with depression.